Course Details
Release Date: 6/3/2026
Expiration Date: 6/3/2029
Credits: 5.25 AMA PRA Category 1 Credits™
This dedicated breast MRI module provides a comprehensive, clinically focused approach to modern breast imaging practice.
This breast MRI program is designed to enhance diagnostic accuracy, improve workflow efficiency, and support high-quality patient care.
Participants will develop the ability to appropriately utilize breast MRI, recognize indications for problem-solving imaging, and appropriate MRI use in diagnostic workflows. The module emphasizes clinical decision-making, imaging selection, and identification of common pitfalls.
Faculty
Program Director
Michael J. Ulissey, MD, FACR
Adjunct Professor
The University of Texas Health
Sciences Center in San Antonio, TX
San Antonio, TX
Faculty
Allyson L. Chesebro, MD
Instructor of Radiology, Harvard
Medical School
Boston, MA
Stamatia Destounis, MD, FACR, FSBI, FAIUM
Attending Breast Radiologist and
Managing Partner Elizabeth Wende
Breast Care
Rochester, NY
Bonnie N. Joe, MD, PhD
Edward A. Sickles Distinguished
Professorship in Radiology
University of California at San
Francisco
San Francisco, CA
Debra L. Monticciolo, MD, FACR, FSBI
Director, Foundation for Imaging
Research and Education
Affl. Faculty, University of Texas at
Austin Dell Medical School of Medicine
Austin, TX
Program
What is New and Updated in the BIRADS 6th Edition | Destounis |
Breast MRI in the High-Risk Patient | Monticciolo |
Radiological Pathological Correlation | Destounis |
Staging the Axilla – a Multimodality Approach | Destounis |
Abbreviated vs Full Protocol Breast MRI | Joe |
Breast MRI in the Newly Diagnosed Cancer Patient | Monticciolo |
NME vs BPE – When to Worry, When to Not | Chesebro |
BIRADS 3 in Breast MRI | Chesebro |
MRI Safety: Devices and Contrast Agents | Joe |
MRI in the Post-Surgical Breast – Reduction, Reconstruction and Implants | Monticciolo |
Breast MRI Biopsy – Tips from Challenging Cases | Chesebro |
What Can We Learn from Difficult MRI Cases | Joe |
Objectives
Educational Objectives
Breast MRI from the National Diagnostic Imaging Symposium®
After completing this activity, participants should be able to:
- Apply evidence-based breast MRI techniques and interpretation strategies for high-risk screening, staging, and diagnostic evaluation.
- Recognize imaging features associated with benign, high-risk, and malignant breast lesions on breast MRI.
- Differentiate suspicious patterns of mass and non-mass enhancement to improve diagnostic accuracy and patient management recommendations.
- Incorporate practical approaches to MRI protocol optimization, image quality assessment, and MRI-guided intervention into daily breast imaging practice.
- Improve interpretation confidence and clinically relevant reporting in complex breast MRI cases, including implant evaluation, treatment assessment, and axillary staging.
Instructions to Receive Credit
Accreditation & Disclosure
ACCREDITATION
World Class CME designates enduring material for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Board of Radiology (ABR) Continuing Certification – AMA PRA Category 1 Credits™ can be used toward ABR MOC lifelong learning requirements.
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
The American Nurses Credentialing Center and the American Academy of Nurse Practitioners Certification Program accept continuing education credits sponsored by organizations, agencies, or educational institutions accredited or approved by the Accreditation Council for Continuing Medical Education (ACCME).
DISCLOSURE
World Class CME relies on all individuals in control of educational content to provide continuing medical education content that is relevant, balanced and evidence based. Therefore, in accordance with ACCME standards, all individuals in control of educational content with relevant financial relationships with ineligible companies will be disclosed and mitigated. Speakers are required to openly disclose any limitations of data and/or any off-label, experimental or investigational uses of drugs or devices in their presentations.
Please click here to view faculty conflict of interest disclosures
